IBI-3028

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameIBI-3028
Drug Alias NameIBI3028IBI-3028
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXinda Biomedical Technology (Hangzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInnovent Biologics (Hangzhou) Co., Ltd.Xinda Biomedical Technology (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A